ArticleDrug delivery2026
Nano spray-dried powders for efficient pulmonary delivery of proteins: an emphasis on comparisons of derived metrics determined by chapters <601> and <1604>.
Article in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary protein delivery has proven to be an effective approach for the treatment of local and systemic diseases, and particles that can be efficiently inhaled into peripheral regions should possess aerodynamic sizes of <2 µm, for which nano-spray-drying (NSD) is a powerful tool for fabrication. However, NSD powders have a high specific surface area and surface energy, which causes severe agglomeration and poor aerosolization performance. To solve these problems, cyclodextrin/leucine delivery systems were constructed, which can evidently protect alkaline phosphatases (AKP) with >94% of their biological activities retained in NSD powders and endow nanoparticle-based AKP-cyclodextrin-leucine (ACL) powders with improved aerosolization behavior. This can be evidenced by the fine particle (<4.46 µm) fraction (FPF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.